Business UpdateAug 5, 2026, 06:12 AM
BetterLife Pharma Prioritizes BETR-001 for Migraine; IND Filing Q1 2027
AI Summary
BetterLife Pharma Inc. announced a strategic prioritization of its lead clinical-stage asset, BETR-001, to target migraine and other primary headache disorders, with an Investigational New Drug (IND) application anticipated in Q1 2027. The company initiated the final IND-enabling GLP toxicology study for BETR-001 and substantially completed GMP manufacturing. Additionally, BetterLife appointed John W. LaRocca, Esq. to its Board of Directors and Audit Committee, granting him 500,000 stock options. The company also raised $335,000 from warrant exercises and $17,500 from stock option exercises, and converted $76,361.65 in convertible debentures into 763,617 units.
Key Highlights
- BETR-001 IND application anticipated in Q1 2027.
- Appointed John W. LaRocca, Esq. to Board of Directors and Audit Committee.
- Granted Mr. LaRocca 500,000 stock options with an exercise price of $0.19.
- Received $335,000 from the exercise of 2,650,000 share purchase warrants.
- Received $17,500 from the exercise of 250,000 stock options.
- Converted $76,361.65 in convertible debentures into 763,617 units.
- Annual General Meeting (AGM) scheduled for October 5, 2026.
Price Impact
More from BETRF